Cartesian Therapeutics (RNAC) Receivables - Other (2020 - 2024)
Cartesian Therapeutics (RNAC) has disclosed Receivables - Other for 5 consecutive years, with $980000.0 as the latest value for Q3 2024.
- Quarterly Receivables - Other fell 47.73% to $980000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $980000.0 through Sep 2024, down 47.73% year-over-year, with the annual reading at $3.0 million for FY2023, 5.72% down from the prior year.
- Receivables - Other for Q3 2024 was $980000.0 at Cartesian Therapeutics, down from $3.5 million in the prior quarter.
- The five-year high for Receivables - Other was $3.5 million in Q2 2024, with the low at $100000.0 in Q2 2021.
- Average Receivables - Other over 5 years is $1.6 million, with a median of $1.3 million recorded in 2021.
- The sharpest move saw Receivables - Other tumbled 90.0% in 2021, then skyrocketed 229.1% in 2024.
- Over 5 years, Receivables - Other stood at $400000.0 in 2020, then tumbled by 75.0% to $100000.0 in 2021, then surged by 3062.0% to $3.2 million in 2022, then dropped by 5.72% to $3.0 million in 2023, then plummeted by 67.13% to $980000.0 in 2024.
- According to Business Quant data, Receivables - Other over the past three periods came in at $980000.0, $3.5 million, and $2.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.